Patents by Inventor Daniele Merico

Daniele Merico has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11578327
    Abstract: The present disclosure provides antisense oligonucleotides, compositions, and methods that target ATP7B exon 6 or a flanking intron, thereby modulating splicing of ATP7B pre-mRNA to increase the level of ATP7B mRNA molecules having exon 6, e.g., to provide a therapy for Wilson disease. The present disclosure provides an antisense oligonucleotide including a nucleobase sequence at least 70% complementary to an ATP7B target sequence in exon 6, a 5?-flanking intron, a 3?-flanking intron, or a combination of exon 6 and the 5?-flanking or 3?-flanking intron.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: February 14, 2023
    Assignee: Deep Genomics Incorporated
    Inventors: Daniele Merico, Erno Wienholds, Frank Schmitges, Matthew O'Hara
  • Publication number: 20220282246
    Abstract: The present disclosure provides antisense oligonucleotides, compositions, and methods that target a ABCA4 exon or intron flanking an exon, thereby modulating splicing of ABCA4 pre-mRNA to increase the level of wild type ABCA4 mRNA molecules, e.g., to provide a therapy for retinitis pigmentosa, cone-rod dystrophy, or Stargardt disease. The present disclosure provides an antisense oligonucleotide including a nucleobase sequence at least 70% complementary to a ABCA4 pre-mRNA target sequence in an intron, 5?-flanking intron, a 3?-flanking intron, or a combination of an exon and the 5?-flanking or 3?-flanking intron.
    Type: Application
    Filed: January 10, 2022
    Publication date: September 8, 2022
    Inventors: Daniele MERICO, Kahlin CHEUNG-ONG
  • Patent number: 11427821
    Abstract: The present disclosure provides compositions and methods for treating a disorder associated with mutations in the CEP290 gene. The disclosure includes synthetic polynucleotides for skipping a reading-frame of a CEP290 pre-RNA, yielding a CEP290 translated product that lacks one or more exons. The disclosure also provides methods of treating patients with the synthetic polynucleotides disclosed herein.
    Type: Grant
    Filed: January 30, 2020
    Date of Patent: August 30, 2022
    Assignee: DEEP GENOMICS INCORPORATED
    Inventors: Daniele Merico, Joao Antonio Lourenco Goncalves, Erno Wienholds, Mark George Ford Sun
  • Publication number: 20220228152
    Abstract: The present disclosure provides antisense oligonucleotides, compositions, and methods that target a LIPA intron flanking exon 8, thereby modulating splicing of LIPA pre-mRNA to increase the level of LIPA mRNA molecules having exon 8, e.g., to provide a therapy for Wolman Disease or Cholesteryl Ester Storage Disease. The present disclosure provides an antisense oligonucleotide including a nucleobase sequence at least 70% complementary to a LIPA pre-mRNA target sequence in a 5?-flanking intron, a 3?-flanking intron, or a combination of exon 8 and the 5?-flanking or 3?-flanking intron.
    Type: Application
    Filed: May 29, 2020
    Publication date: July 21, 2022
    Inventors: Daniele MERICO, Kahlin CHEUNG-ONG, Mark SUN
  • Publication number: 20210032629
    Abstract: The present disclosure provides antisense oligonucleotides, compositions, and methods that target ATP7B exon 6 or a flanking intron, thereby modulating splicing of ATP7B pre-mRNA to increase the level of ATP7B mRNA molecules having exon 6, e.g., to provide a therapy for Wilson disease. The present disclosure provides an antisense oligonucleotide including a nucleobase sequence at least 70% complementary to an ATP7B target sequence in exon 6, a 5?-flanking intron, a 3?-flanking intron, or a combination of exon 6 and the 5?-flanking or 3?-flanking intron.
    Type: Application
    Filed: February 14, 2019
    Publication date: February 4, 2021
    Inventors: Daniele MERICO, Erno WIENHOLDS, Frank SCHMITGES, Matthew O'HARA
  • Publication number: 20200165611
    Abstract: The present disclosure provides compositions and methods for treating a disorder associated with mutations in the CEP290 gene. The disclosure includes synthetic polynucleotides for skipping a reading-frame of a CEP290 pre-RNA, yielding a CEP290 translated product that lacks one or more exons. The disclosure also provides methods of treating patients with the synthetic polynucleotides disclosed herein.
    Type: Application
    Filed: January 30, 2020
    Publication date: May 28, 2020
    Inventors: Daniele Merico, Joao Antonio Lourenco Goncalves, Erno Wienholds, Mark George Ford Sun